Soleno Therapeutics, Inc. (FRA:6XC)
Germany · Delayed Price · Currency is EUR | Market Cap | 2.33B -6.0% |
| Revenue (ttm) | 162.17M |
| Net Income | 17.44M |
| EPS | 0.33 |
| Shares Out | n/a |
| PE Ratio | 133.76 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 6 |
| Open | 43.95 |
| Previous Close | 44.42 |
| Day's Range | 43.90 - 43.95 |
| 52-Week Range | 25.50 - 76.65 |
| Beta | n/a |
| RSI | 70.00 |
| Earnings Date | May 8, 2026 |
About Soleno Therapeutics
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California. [Read more]
News
Folia Health Launches “BRAVE-PWS” Study to Better Understand the Real-World Experience of Prader-Willi Syndrome Caregivers
Folia Health's fully remote, app-based study sponsored by Soleno Therapeutics follows PWS caregivers over six months to capture their daily experiences.
Are TERN, SLNO, WSR Obtaining Fair Deals for their Shareholders?
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers.
SOLENO THERAPEUTICS, INC. (SLNO) DEADLINE ALERT Bernstein Liebhard LLP Reminds Soleno Therapeutics, Inc. Investors of Upcoming Deadline
NEW YORK, April 09, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Soleno Therapeutics, Inc. (NASDAQ: SLNO)? Did you purchase your shares between March 26, 2025 and...
Soleno withdraws EU rare disease drug application ahead of Neurocrine takeover
Soleno Therapeutics said on Tuesday it has voluntarily withdrawn the European marketing application for its rare metabolic disorder drug following acquirer Neurocrine's plans to sharpen focus on the...
Neurocrine to Buy Soleno for $2.9 Billion
Neurocrine Biosciences agreed to buy Soleno Therapeutics for $2.9 billion in a move intended to expand its endocrinology and rare-disease portfolio.
Neurocrine to buy Soleno Therapeutics for $2.9 billion
Neurocrine Biosciences will acquire rare disease drugmaker Soleno Therapeutics for $2.9 billion in cash, the companies said on Monday.
Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio
VYKAT™ XR (diazoxide choline) is the First and Only FDA Approved Treatment for Hyperphagia in Prader-Willi Syndrome and Represents a Transformative Therapy Expands Neurocrine's High-Growth Commercia...
Soleno (SLNO) Sued After DCCR Launch Setback, Share Drop-- Hagens Berman
SAN FRANCISCO, April 1, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Soleno Therapeutics, Inc. (NASDAQ: SLNO) seeking to represent investors who purchased Soleno commo...
SLNO Stockholders Have Rights – If You Lost Money Investing in Soleno Therapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses
Robbins LLP is Investigating Allegations that Soleno Therapeutics SLNO Misled Investors Regarding the Viability and Efficacy of its Phase 3 Clinical Trial
Notice to Long-Term Investors of Soleno Therapeutics, Inc. (SLNO): Grabar Law Office Investigates Claims on Your Behalf
Philadelphia, Pennsylvania--(Newsfile Corp. - March 13, 2026) - Grabar Law Office is investigating claims on behalf of shareholders of Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SL...
SLNO Lawsuit Alleges Allegedly Conducting Sham Clinical Trials - Soleno Therapeutics, Inc. Investors Face Losses Following Allegedly Conducting Sham Clinical Trials: SueWallSt
Alert: Claims Focus on Alleged Misrepresentations About Clinical Trial Integrity and Drug Safety NEW YORK, March 12, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of Soleno Therapeutic...
Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT™ XR
REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases,...
Soleno Therapeutics Announces Publication of Results from Pivotal Study of VYKAT™ XR in the Journal of Clinical Endocrinology and Metabolism
REDWOOD CITY, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases,...
Johnson Fistel Begins Investigation on Behalf of Soleno Therapeutics, Inc. (SLNO) Shareholders Who Have Incurred Losses
SAN DIEGO , Dec. 15, 2025 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, PLLP is investigating whether Soleno Therapeutics, Inc. (NASDAQ: SLNO) or certain of its officers and directors vi...
Soleno Therapeutics Announces the Passing of Board Member William G. Harris
REDWOOD CITY, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases,...
Soleno Therapeutics (SLNO) Faces Investor Scrutiny Amid Disappointing VYKAT XR Starts, Discontinuations; Shares Down 26% – Hagens Berman
SAN FRANCISCO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO) saw the price of their shares tumble $18.78 (-28%) after the company reported disappointing infor...
Soleno Therapeutics, Inc. Investigated by the Portnoy Law Firm
LOS ANGELES, Nov. 12, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Soleno Therapeutics, Inc., (“Soleno" or the "Company") (NASDAQ: SLNO) investors that the firm has initiated an investigation...
Soleno Therapeutics Announces Entry Into $100 Million Accelerated Share Repurchase Agreement
REDWOOD CITY, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare disease...
Soleno Therapeutics (SLNO) Faces Investor Scrutiny Amid Disappointing VYKATÔ XR Starts, Discontinuations; Shares Down 26% -- Hagens Berman
SLNO Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO , Nov. 7, 2025 /PRNewswire/ -- On November 5, 2025, investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO) saw the price of ...
Soleno Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on U.S. Launch of VYKAT(TM) XR
REDWOOD CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases,...
Soleno Therapeutics to Participate in Upcoming November Conferences
REDWOOD CITY, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare disease...
Soleno Therapeutics (SLNO) Drops Amid Critical Scorpion Report -- Hagens Berman
SAN FRANCISCO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- On August 15, 2025, shares in Soleno Therapeutics, Inc. (NASDAQ: SLNO) experienced a significant drop following the release of a highly critical report...
SOLENO (SLNO) REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors of the Investigation into Soleno Therapeutics, Inc. and Encourages Investors to Contact the Firm
Scorpion Capital alleged Soleno's sole product, Vykat XR, was overpriced and unsafe for children, causing shares to drop 7.4% to $71.63 on August 15, 2025.
Soleno Therapeutics, Inc. (SLNO) Under Investigation After Scorpion Capital Report Raises Drug Safety Concerns; Investors Urged to Contact Award-Winning Firm, Gibbs Mura
OAKLAND, Calif.--(BUSINESS WIRE)---- $SLNO #SLNO--Gibbs Mura is investigating legal claims on behalf of investors of Soleno Therapeutics, Inc. (NASDAQ: SLNO).
SLNO Investors Have Opportunity to Join Soleno Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $SLNO--SLNO Investors Have Opportunity to Join Soleno Therapeutics, Inc. Fraud Investigation with the Schall Law Firm.